More Americans Will Only Have to Pay $35 a Month for Insulin in 2024

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 2, 2024.

By Robin Foster HealthDay Reporter

TUESDAY, Jan. 2, 2024 -- Managing diabetes will be a less expensive proposition for more Americans in 2024.

Sanofi has officially joined Novo Nordisk and Eli Lilly in lowering the cost of insulin to $35 a month for many patients. The three drugmakers are also drastically lowering the list prices for their insulin products.

The price-cutting moves were first announced last spring, but some of them didn’t take effect until Jan. 1.

After spending on insulin had tripled in the past decade, drug makers had come under heavy fire from patients and politicians alike. In 2022, $22.3 billion was spent on insulin costs, compared to just $8 billion in 2012, according to the American Diabetes Association (ADA).

Over 8 million Americans need insulin to survive, but up to quarter of those patients haven't been able to afford the medication and have dangerously rationed doses, according to the ADA.

Now, thanks to the Inflation Reduction Act, Medicare enrollees pay no more than $35 a month for their insulin prescriptions.

But they are not the only ones getting price breaks.

As of Jan. 1, Sanofi established a $35 monthly cap on out-of-pocket costs for Lantus, its most widely prescribed insulin in the United States, for all patients with commercial insurance. It already limits the cost to $35 for all uninsured patients.

In September, Novo Nordisk launched the MyInsulinRx program, which provides a 30-day supply of insulin for $35 to eligible patients, including the uninsured. The company also offers a co-pay savings card that allows eligible patients to buy its insulin products for as little as $35 and no more than $99, depending on their health insurance coverage.

And in March, Eli Lilly instituted an automatic $35 monthly cap on out-of-pocket costs for those with commercial insurance buying its insulin products at participating retail pharmacies. The uninsured can download the Lilly Insulin Value Program savings card, which allows them to get the medication for $35 a month.

All three companies are also lowering the list prices for many of their insulin products, CNN reported.

Sanofi cut the list price of Lantus by 78%, to $96 for the prefilled pens and $64 for the 10-milliliter vial, starting Jan. 1. It also reduced the list price of its short-acting Apidra insulin by 70%.

Meanwhile, Novo Nordisk lowered the list prices of several of its insulin vials and prefilled pens by up to 75%, as of Jan. 1. The new list price for NovoLog is $72 per vial and $140 for the FlexPen.

And Eli Lilly slashed the list prices of Humalog, its most commonly prescribed insulin, and of Humulin by 70% by the end of 2023. Humalog will now carry a list price of $66 per vial.

Still, these moves will save the companies hundreds of millions of dollars a year, experts told CNN. That's because the 2021 American Rescue Plan Act changed rebates that drug manufacturers pay annually to state Medicaid programs -- a change that kicked in on Jan. 1.

Sources

  • CNN

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-01-03 00:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords